6 active
/
26 total (since 2015)
1
Phase 1 Active
8 total
2
Phase 2 Active
11 total
3
Phase 3 Active
8 total
0
Phase 4 Active
0 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Crinetics Pharmaceuticals Inc. 3 2 0
Debiopharm International SA 1 0 1
AstraZeneca 1 0 0
Marea Therapeutics 1 0 0
Camurus AB 0 3 0
Ionis Pharmaceuticals, Inc. 0 3 0
NCT05192382 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Crinetics Pharmaceuticals Inc. n=111
NCT04837040 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals Inc. n=58
NCT06930625 RECRUITING
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA n=119
NCT04125836 COMPLETED
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=135
NCT04076462 COMPLETED
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=72
NCT02685709 COMPLETED
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Chiasma, Inc. n=146
NCT02354508 COMPLETED
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis Pharmaceuticals n=123
Data: ClinicalTrials.gov